Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;59(2):505-8.
doi: 10.2337/db09-0583.

Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome

Michael P Brugts  1 , Cornelia M van Duijn, Leo J Hofland, Jacqueline C Witteman, Steven W J Lamberts, Joseph A M J L Janssen
Affiliations

Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome

Michael P Brugts et al. Diabetes. 2010 Feb.

Abstract

Objective: There is a complex relationship between IGF-I, IGF binding proteins, growth hormone, and insulin. The IGF-I kinase receptor activation assay (KIRA) is a novel method for measuring IGF-I bioactivity in human serum. We speculated that determination of IGF-I bioactivity might broaden our understanding of the IGF-I system in subjects with the metabolic syndrome. The purpose of our study was to investigate whether IGF-I bioactivity was related to insulin sensitivity and the metabolic syndrome.

Research design and methods: We conducted a cross-sectional study embedded in a random sample (1,036 elderly subjects) of a prospective population-based cohort study. IGF-I bioactivity was determined by the IGF-I KIRA. Categories of glucose (in)tolerance were defined by the 2003 American Diabetes Association criteria. Insulin sensitivity was assessed by homeostasis model assessment. The Adult Treatment Panel III definition of the metabolic syndrome was used.

Results: In subjects with normal fasting glucose and impaired fasting glucose, IGF-I bioactivity progressively increased with increasing insulin resistance, peaked at fasting glucose levels just below 7.0 mmol/l, and dropped at higher glucose levels. Mean IGF-I bioactivity peaked when three criteria of the metabolic syndrome were present and then declined significantly when five criteria of the metabolic syndrome were present.

Conclusions: We observed that IGF-I bioactivity was related to insulin sensitivity, insulin levels, and the metabolic syndrome. Our study suggests that there exists an inverse U-shaped relationship between IGF-I bioactivity and number of components of the metabolic syndrome. This observation contrasts with previous results reporting an inverse relationship between total IGF-I and components of the metabolic syndrome.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Mean ± SEM IGF-I bioactivity stratified per decile of HOMA-IR. Statistical differences between deciles were calculated after adjustment for age, BMI, and sex. P for trend < 0.001, **P = 0.005.
FIG. 2.
FIG. 2.
Relationship between the number of components of the metabolic syndrome and mean ± SEM IGF-I bioactivity. *P = 0.03, **P = 0.04.
See this image and copyright information in PMC

References

    1. Yuen KC, Dunger DB: Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab 2007;9:11–22 - PubMed
    1. O'Connell T, Clemmons DR: IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 2002;87:4356–4360 - PubMed
    1. Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA: Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995;80:1312–1317 - PubMed
    1. Ji S, Guan R, Frank SJ, Messina JL: Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway. J Biol Chem 1999;274:13434–13442 - PubMed
    1. Xu J, Ji S, Venable DY, Franklin JL, Messina JL: Prolonged insulin treatment inhibits GH signaling via STAT3 and STAT1. J Endocrinol 2005;184:481–492 - PubMed

Publication types

Substances